Coronavirus / COVID

Preprint data from a real-world evidence assessment, as well as preliminary reports from a 2-dose trial, support the company's pursuit for FDA authorization of a second COVID-19 vaccine dose.

The data, which reflects pre-pandemic routine vaccination levels, showed human papillomavirus vaccine rates increased among teens ages 13-17.

A smaller dosage was used and with their results the two companies plan to submit their data to governmental regulatory agencies around the world.

The Centers for Disease Control and Prevention's (CDC) VISION Network of health care systems provided data for test-negative design analysis of vaccine effectiveness in preventing COVID-19 acute admissions.

After voting against recommendation of a booster dose for people 16 years and older, the committee created a new question to vote on an EUA for a booster dose for people 65 years and older and those at high risk of COVID-19. They voted 18-0 in favor.

The VRBPAC voted 16-2 on Friday afternoon on the question they were presented.

A new study addressed the clinical outcomes in young adults who were hospitalized with COVID-19 across the United States.

A Food and Drug Administration (FDA) committee will discuss this topic as it pertains to the potential approval of a third dose of the Pfizer-BioNTech COVID-19 vaccine. The results of this meeting could have ramifications for the Biden Administration’s COVID-19 health policy.

The emergency authorization granted to combination bamlanivimab and etesevimab is the second indicated in this last year.

Based on recent studies, the company sees benefits in administering booster doses.

Recent data shows that all three COVID-19 vaccines being administered in the United States are showing high rates of vaccine effectiveness (VE).

Though efficacy waned over months, protection from symptomatic and severe COVID-19 remained significant, with no new adverse event risks observed.

In a recent speech, Pfizer’s CFO says it might be a matter of weeks for submitting an application for children 6 months to 5 years old.

A study from Mexico shows that maternal mortality increased nearly 60 percent during the COVID-19 pandemic, and reaffirms the importance of both COVID-19 and influenza vaccinations for pregnant women.

Greatest risk for infection among vaccinated may be at home rather than at work, researchers say.

This decision is in spite of the government’s vaccine group saying that vaccines only marginally benefit this age group.

Pfizer-BioNTech and Moderna mRNA vaccines provoke different levels of antibody response within and between age groups.

Even with the Delta variant as the predominant strain now, a group scientists concluded that vaccine efficacy against severe COVID-19 is so high that booster doses for the general population are not appropriate at this stage in the pandemic.

The antibody profile in the blood of patients who have had the virus is extremely variable and this may modify the response to the treatment.

In a large study looking at incidence rates for hospitalization and mortality, results changed relatively little in terms of vaccine effectiveness, even after the Delta variant became the dominant strain.

The co-founders of BioNTech said they expect to present US and European regulators with data soon for children 5-11 years old.

With a noticeable frustration, President Joe Biden laid out a plan last night to combat the pandemic with employer mandates and other initiatives.

In a move that is going to be announced, the administration is going to look to mandate vaccines for any companies with 100 employees or more

The shot will be its NanoFlu/NVX-CoV2373 vaccine using the company’s Matrix-M adjuvant platform.

A new study looked at the naturally-acquired spike immunoglobin (Ig) G antibodies, and how they hold up against neutralization and protect us against future infection.